Annual report pursuant to Section 13 and 15(d)

Debt - Textual (Details)

v3.3.1.900
Debt - Textual (Details)
 1 Months Ended 12 Months Ended
Nov. 05, 2015
USD ($)
Apr. 01, 2015
d
$ / shares
Aug. 30, 2013
USD ($)
conversion_right
Rate
shares
Jun. 30, 2014
USD ($)
shares
Jan. 31, 2013
USD ($)
$ / shares
Rate
Dec. 31, 2015
USD ($)
institution
$ / shares
Rate
shares
Dec. 31, 2014
USD ($)
institution
$ / shares
Rate
Dec. 31, 2013
USD ($)
$ / shares
Rate
Aug. 31, 2015
USD ($)
Jan. 30, 2013
USD ($)
Debt Instrument [Line Items]                    
Interest paid           $ 4,572,000 $ 6,276,000 $ 3,407,000    
Gains (losses) on extinguishment of debt           (943,000) (2,668,000) (972,000)    
Gain (loss) on embedded derivative           36,600,000 12,200,000      
Credit line capacity           189,823,000        
Net assets [1]           1,979,794,000 842,144,000      
Goodwill           $ 743,348,000 [1] $ 224,292,000 [1] 226,373,000    
Number of financial institutions | institution           10 10      
Bio-Reference Laboratories, Inc.                    
Debt Instrument [Line Items]                    
Net assets           $ 1,000,000,000        
Goodwill           441,158,000     $ 441,158,000  
Intangible assets           528,300,000     $ 542,900,000  
OPKO Health Europe                    
Debt Instrument [Line Items]                    
Goodwill           8,062,000        
Intangible assets           $ 8,378,000        
Weighted average interest rate           4.30% 3.40%      
Minimum | OPKO Health Europe                    
Debt Instrument [Line Items]                    
Variable interest rates           2.40%        
Maximum | OPKO Health Europe                    
Debt Instrument [Line Items]                    
Variable interest rates           6.30%        
Notes                    
Debt Instrument [Line Items]                    
Principal balance           $ 49,412,000 $ 131,454,000 $ 211,912,000    
Notes | Notes Due February 1, 2033                    
Debt Instrument [Line Items]                    
Debt face amount                   $ 175,000,000.0
Interest rate of notes payable           3.00% 3.00%     3.00%
Equivalent redemption price         100.00%          
Conversion rate | Rate     14148.00%   14148.27% 14148.27% 14148.27% 14148.27%    
Conversion principal amount     $ 1,000   $ 1,000          
Conversion Price | $ / shares   $ 7.07     $ 7.07 $ 7.07 $ 7.07 $ 7.07    
Convertible debt, threshold percentage of stock price trigger   130.00%     130.00% 130.00%        
Number of consecutive trading days applicable conversion price   30 days                
Conversion rights triggered | conversion_right     1              
Threshold trading days | d   3                
Convertible notes, conversion     $ 16,900,000     $ 55,400,000        
Convertible debt, stock issued from conversion | shares     2,396,145     8,118,062        
Interest paid       $ 800,000            
Gains (losses) on extinguishment of debt       (2,700,000)   $ (900,000)        
Gain on conversion     $ 1,000,000              
Converted amount       $ 70,400,000            
Common stock trigger price | $ / shares   $ 9.19       $ 9.19        
Principal balance           $ 32,200,000 $ 87,600,000 $ 158,100,000    
Notes | Notes Due February 1, 2033 | Minimum                    
Debt Instrument [Line Items]                    
Number of trading days         20 days 20 days        
Notes | Notes Due February 1, 2033 | Maximum                    
Debt Instrument [Line Items]                    
Number of consecutive trading days applicable conversion price         30 days 30 days        
Notes | Notes Due February 1, 2033 | On or after February 1, 2017 and before February 1, 2019                    
Debt Instrument [Line Items]                    
Equivalent redemption price         100.00%          
Line of Credit                    
Debt Instrument [Line Items]                    
Weighted average interest rate           4.30% 6.10%      
Common stock investments, available for sale | Notes | Notes Due February 1, 2033                    
Debt Instrument [Line Items]                    
Convertible debt, stock issued from conversion | shares       10,974,431            
Revolving Credit Facility | Line of Credit | New Credit Agreement                    
Debt Instrument [Line Items]                    
Credit line capacity $ 175,000,000.0                  
Higher borrowing capacity option $ 275,000,000.0                  
Commitment fee percentage 0.25%                  
Bridge Loan | Line of Credit | New Credit Agreement                    
Debt Instrument [Line Items]                    
Credit line capacity $ 20,000,000.0                  
Letter of Credit | Line of Credit | New Credit Agreement                    
Debt Instrument [Line Items]                    
Credit line capacity $ 20,000,000.0                  
LIBOR | Revolving Credit Facility | Line of Credit | New Credit Agreement                    
Debt Instrument [Line Items]                    
Basis spread on variable rate 2.50%                  
LIBOR, First 12 Months | Revolving Credit Facility | Line of Credit | New Credit Agreement                    
Debt Instrument [Line Items]                    
Basis spread on variable rate 0.35%                  
LIBOR, thereafter | Revolving Credit Facility | Line of Credit | New Credit Agreement                    
Debt Instrument [Line Items]                    
Basis spread on variable rate 0.50%                  
LIBOR, First 12 Months, Adjusted for Eurocurrency Liabilities | Revolving Credit Facility | Line of Credit | New Credit Agreement                    
Debt Instrument [Line Items]                    
Basis spread on variable rate 1.35%                  
LIBOR, Thereafter, Adjusted for Eurocurrency Liabilities | Revolving Credit Facility | Line of Credit | New Credit Agreement                    
Debt Instrument [Line Items]                    
Basis spread on variable rate 1.50%                  
[1] As of December 31, 2014, total assets include $7.6 million and total liabilities include $12.1 million related to SciVac Ltd (“SciVac”). SciVac was a consolidated variable interest entity which we deconsolidated in July 2015. Refer to Note 4. SciVac’s consolidated assets were owned by SciVac and SciVac’s consolidated liabilities had no recourse against us.